The Big Pharma superpowers are on the edge of a patent cliff. The combination of patent expirations, uncertain product and patent pipelines, and expiring regulatory exclusivities will negatively impact a host of Big Pharma blockbuster products. Due to these factors, pharma firms are set to lose approximately $200 billion in revenue between now and 2030 to generic and biosimilar competitors. And with a shortage of new products coming down research and development (R&D) pipelines, Big Pharma is in an IP and regulatory race to replace lose profits and maintain market exclusivity. Life Sciences partners Alicia Palladino and Daniel Scolnick explain more in The Licensing Journal, which they co-authored.